Skip to search formSkip to main contentSkip to account menu

Probucol

Known as: Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole, 4,4'- (Isopropylidenedithio)bis(2,6-di-tert-butylphenol), Probucol [Chemical/Ingredient] 
A bis-phenol antioxidant with antilipidemic activity. Probucol inhibits oxidation of low density lipoprotein and lowers the level of cholesterol in… 
National Institutes of Health

Related topics

Related topics

28 relations

Broader (2)

Anticholesteremic AgentsAntioxidants
Antilipemic agentCoronary Artery DiseaseDrug AllergyGall Bladder Diseases

Narrower (11)

BiphenabidCGP 2881DH-581Lesterol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2002
Highly Cited
2002
Effects of inhibition of glycation and oxidative stress on the development of diabetic nephropathy in rats.
Highly Cited
1999
Highly Cited
1999
Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical…
Highly Cited
1996
Highly Cited
1996
In vitro antioxidant effects of estrogens with a hindered 3-OH function on the copper-induced oxidation of low density lipoprotein
Highly Cited
1996
Highly Cited
1996
Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol.
We attempted to demonstrate selective modulation of lipid-free apolipoprotein-mediated cellular lipid efflux in order to test the… 
Highly Cited
1995
Highly Cited
1995
Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST…
The aim of the Probucol Quantitative Regression Swedish Trial (PQRST) (n = 303) was to investigate whether probucol (0.5 g BID… 
Highly Cited
1994
Highly Cited
1994
SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant.
Highly Cited
1992
Highly Cited
1992
The oxidative modification of low density lipoprotein by human lymphocytes.
Highly Cited
1992
Highly Cited
1992
Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.
To determine whether probucol's ability to confer antioxidant protection to low density lipoprotein (LDL) could be dissociated… 
Highly Cited
1991
Highly Cited
1991
Oxidative modification of glycated low density lipoprotein in the presence of iron.
Highly Cited
1984
Highly Cited
1984
Influence of probucol on cholesterol and lipoprotein metabolism in man.
The mechanisms for the hypocholesterolemic action of probucol were examined in 17 patients with various levels of plasma… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)